For all of the men out there dealing with the effects of being prescribed Risperdal, we would like to offer a Risperdal gynecomastia lawsuit update. According to our sources, there is a settlement in process that is in the ballpark of 1.4 million dollars per claimant. This will more than cover the cost of the reconstructive surgery that many of the victims in the Risperdal gynecomastia lawsuit face, but it will more than compensate them for the emotional damage that an injury so personal may have caused.
The common warning signs of gynecomastia include:
- swelling and soreness in the breast tissue in men
- Abnormal growth of the breast tissue
There are quite a few claimants involved in this suit, but there are still many more out there. We would like to extend our services to those men who are too ashamed or even just going through this alone. We want to tell you that you are not alone and we are going to continue to reach out to potential claimants and encourage them to join our crusade against these drug companies that lack integrity and only have their bottom line in mind. We want you to know that the more people begin to stand up for the rights they have and don’t exercise, the more these rights will be relevant in their daily lives.
To all of the victims in the risperdal gynecomastia lawsuit, we invite you all to come together against Jonson and Johnson for withholding this information from you that caused this condition. The more voices we have speaking on this injustice, the louder and clearer our point becomes.
If you or any of your loved ones have been diagnosed with gynecomastia after taking Risperdal, please fill out the claims form at the top of the page and we would be happy to fight diligently for the compensation you deserve.
One of the newer and horrible settlements to come p recently is is the zofran lawsuit. Zofran much like risperdal was marketed off label. It was given to pregnant mothers to stop nausea. It was originally only approved for chemo patients. The zofran birth defects are devastating.